Pascal Biosciences Inc (TSE:NEVI)
:NEVI
NEVI Stock Chart & Stats
C$0.07
C$0.00(0.00%)
At close: 4:00 PM EST
C$0.07
C$0.00(0.00%)
Day’s Range― - ―
52-Week RangeC$0.03 - C$0.10
Previous CloseN/A
Volume0.00
Average Volume (3M)55.49K
Market Cap
C$1.39M
Enterprise ValueC$1.53M
Total Cash (Recent Filing)C$102.17K
Total Debt (Recent Filing)C$244.21K
Price to Earnings (P/E)―
Beta2.24
Next Earnings
Apr 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding39,662,727
10 Day Avg. Volume84,932
30 Day Avg. Volume55,489
Financial Highlights & Ratios
PEG Ratio0.26
Price to Book (P/B)2.05
Price to Sales (P/S)1.17
P/FCF Ratio31.93
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Accelerating Revenue GrowthRevenue acceleration into 2025 indicates expanding top-line traction and improving product or market adoption. A durable upward revenue trend supports operating leverage over time, providing a basis for margin recovery and capacity to invest in growth if management sustains execution.
Positive Operating & Free Cash FlowTurning operating and free cash flow positive demonstrates improved cash generation and discipline versus prior years. Consistent positive cash flow reduces reliance on external financing and gives the company durable flexibility to fund operations, capex or working capital needs.
Improving LeverageLower leverage enhances financial resilience and reduces fixed servicing burden, improving the company's ability to weather volatility. A sustained decline in debt ratio provides structural optionality for reinvestment or strategic initiatives without immediate liquidity pressure.
Bears Say
Persistent Net LossesDespite improvement, continued negative net margins indicate the company has not yet reached sustainable profitability. Persistent losses erode equity and constrain reinvestment capacity, meaning profitability must improve structurally to support long-term growth without recurring capital raises.
Severe Gross Margin CompressionA dramatic drop in gross margin signals structural cost, pricing or product-mix pressure that undermines sustainable profitability. Unless margins recover through pricing power or cost fixes, the company may struggle to convert revenue growth into durable operating profits and cash flow.
Historical Balance Sheet FragilityPast episodes of negative equity reflect structural vulnerability in the capital base; if losses persist, the balance sheet could again weaken, forcing dilutive financing or higher-cost capital. This legacy fragility makes sustained profitability and cash generation critical for long-term stability.
Pascal Biosciences Inc News
NEVI FAQ
What was Pascal Biosciences Inc’s price range in the past 12 months?
Pascal Biosciences Inc lowest stock price was C$0.03 and its highest was C$0.10 in the past 12 months.
What is Pascal Biosciences Inc’s market cap?
Pascal Biosciences Inc’s market cap is C$1.39M.
When is Pascal Biosciences Inc’s upcoming earnings report date?
Pascal Biosciences Inc’s upcoming earnings report date is Apr 24, 2026 which is in 15 days.
How were Pascal Biosciences Inc’s earnings last quarter?
Currently, no data Available
Is Pascal Biosciences Inc overvalued?
According to Wall Street analysts Pascal Biosciences Inc’s price is currently Overvalued.
Does Pascal Biosciences Inc pay dividends?
Pascal Biosciences Inc does not currently pay dividends.
What is Pascal Biosciences Inc’s EPS estimate?
Pascal Biosciences Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Pascal Biosciences Inc have?
Pascal Biosciences Inc has 39,662,727 shares outstanding.
What happened to Pascal Biosciences Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Pascal Biosciences Inc?
Currently, no hedge funds are holding shares in TSE:NEVI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Pascal Biosciences Inc
Nevis Brands Inc. develops and markets cannabis products in the United States. Its flagship brand is Major, a cannabis beverage. The company was formerly known as Pascal Biosciences Inc. and changed its name to Nevis Brands Inc. in June 2023. Nevis Brands Inc. is headquartered in Seattle, Washington.
Technical Analysis
TAAT Global Alternatives
―
West Island Brands Inc
―
Modern Meat
―
Lifeist Wellness
―
Element Nutritional Sciences Inc
―
Options Prices
Currently, No data available
---